{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T03:58:47Z","timestamp":1774497527794,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ijrobp.2021.07.1711","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T01:27:32Z","timestamp":1627867652000},"page":"158-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Establishing Cost-Effective Allocation of Proton Therapy for Patients With Mediastinal Hodgkin Lymphoma"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0616-034X","authenticated-orcid":false,"given":"Raymond B.","family":"Mailhot Vega","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Homan","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir I.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam L.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie A.","family":"Lockney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha M.","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William B.","family":"Slayton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan K.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradford S.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy P.","family":"Mendenhall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0001","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0002","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"Engert","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0003","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0004","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable hodgkin lymphoma: Final results of the international, randomized Phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0005","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II hodgkin lymphoma: Final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andre","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0006","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1053\/clon.2002.0174","article-title":"The relative costs of proton and x-ray radiation therapy","volume":"15","author":"Goitein","year":"2003","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0007","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1200\/JCO.2017.72.6414","article-title":"Untapped potential of observational research to inform clinical decision making: American Society Of Clinical Oncology research statement","volume":"35","author":"Visvanathan","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0008","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/cncr.29882","article-title":"A systematic review of the cost and cost-effectiveness studies of proton radiotherapy","volume":"122","author":"Verma","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0009","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study group HD14 trial","volume":"30","author":"von Tresckow","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0010","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0011","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0012","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.1996.03540140060028","article-title":"The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine","volume":"276","author":"Russell","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0013","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness: The curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0014","unstructured":"Centers for Disease Control and Prevention. CDC Wonder. 2020. Available at: https:\/\/wonder.cdc.gov\/. Accessed November 10, 2019."},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0015","unstructured":"Medical care in US city average, all urban consumers, not seasonally adjusted. Available at: https:\/\/data.bls.gov\/timeseries\/CUUR0000SAM?output_view=pct_12mths. Accessed November 11, 2019."},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0016","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1002\/cncr.28322","article-title":"Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma","volume":"119","author":"Mailhot Vega","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0017","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2016.02.031","article-title":"Establishing cost-effective allocation of proton therapy for breast irradiation","volume":"95","author":"Mailhot Vega","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0018","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0360-3016(00)00427-2","article-title":"A comparison of two methods for estimating the technical costs of external beam radiation therapy","volume":"47","author":"Hayman","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0019","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/13696998.2018.1542599","article-title":"Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma","volume":"22","author":"Delea","year":"2019","journal-title":"J Medical Econ"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0021","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/bjh.14316","article-title":"Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma","volume":"175","author":"Ramsey","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0022","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3109\/10428194.2014.970542","article-title":"Health utilities in relation to treatment response and adverse events in relapsed\/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"56","author":"Swinburn","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0023","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0272989X06290495","article-title":"Preference-based EQ-5D index scores for chronic conditions in the United States","volume":"26","author":"Sullivan","year":"2006","journal-title":"Med Decis Making"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0024","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jash.2009.09.001","article-title":"Costs associated with cardiovascular events in patients with hypertension in US managed care settings","volume":"3","author":"Duh","year":"2009","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0025","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMsa1616035","article-title":"Cost-effectiveness of intensive versus standard blood-pressure control","volume":"377","author":"Bress","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0026","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2147\/CEOR.S178649","article-title":"Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure","volume":"10","author":"Bonafede","year":"2018","journal-title":"ClinicoEcon Outcomes Res"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0027","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jama.1996.03540160061034","article-title":"Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine","volume":"276","author":"Siegel","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0028","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.amjcard.2012.05.046","article-title":"Recent trends in post-discharge mortality among patients with an initial acute myocardial infarction","volume":"110","author":"Coles","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0029","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.prro.2019.09.015","article-title":"The meaningless meaning of mean heart dose in mediastinal lymphoma in the modern radiation therapy era","volume":"10","author":"Hoppe","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0030","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.radonc.2020.07.056","article-title":"First experience with model-based selection of head and neck cancer patients for proton therapy","volume":"151","author":"Tambas","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0031","unstructured":"Landelijk Platform voor Radiotherapie BIJ Longtumoren (LPRL) & Landelijk Platform Protonentherapie (LPPT). Landelijk Indicatie Protocol Protonen Therapie. National Indication Proton Protocol for Thorax, 2019. Available at: https:\/\/nvro.nl\/images\/documenten\/rapporten\/LIPP_longen_final_01122019.pdf. Accessed March 1, 2021."},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0032","unstructured":"Social Security Administration. Period life table, 2017. Available at: https:\/\/www.ssa.gov\/oact\/STATS\/table4c6.html. Accessed December 4, 2020."},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0033","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/CIR.0000000000000366","article-title":"Executive summary: Heart disease and stroke statistics\u20142016 update: A report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.ijrobp.2021.07.1711_bib0034","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/hon.2070","article-title":"XII. Hodgkin lymphoma in older patients: Challenges and opportunities to improve outcomes","volume":"31","author":"Jagadeesh","year":"2013","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0035","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ijrobp.2017.05.004","article-title":"Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) lymphoma subcommittee","volume":"99","author":"Tseng","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0036","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1111961","article-title":"ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma","volume":"366","author":"Meyer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0037","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2014.050","article-title":"Hodgkin's lymphoma in older patients: An orphan disease?","volume":"6","author":"Thyss","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0038","doi-asserted-by":"crossref","unstructured":"Dabaja BS, Hoppe BS, Plastaras JP, et\u00a0al. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood. 2018;132:1635-1646.","DOI":"10.1182\/blood-2018-03-837633"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0039","unstructured":"Heart disease statistics and maps. 2020. Available at:https:\/\/www.cdc.gov\/heartdisease\/facts.htm#:\u223c:text=Heart%20Disease%20in%20the%20United,United%20States%20from%20cardiovascular%20disease. Accessed June 2, 2020."},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0040","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0041","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1200\/JCO.2016.69.8480","article-title":"Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures","volume":"35","author":"van den Bogaard","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.07.1711_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14338\/IJPT-20-00010.1","article-title":"Reducing heart dose with protons and cardiac substructure sparing for mediastinal lymphoma treatment","volume":"7","author":"Taparra","year":"2020","journal-title":"Int J Part Ther"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621026249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621026249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:54:13Z","timestamp":1759744453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301621026249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0360301621026249"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.07.1711","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Establishing Cost-Effective Allocation of Proton Therapy for Patients With Mediastinal Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.07.1711","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}